Real-World Study of Delgocitinib Cream for Chronic Hand Eczema
Part of Skin clinical trials.
This study tracks how well delgocitinib cream works and how safe it is for people with chronic hand eczema in everyday use. Researchers collect information from your doctor visits to understand if this treatment helps manage your hand eczema symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with chronic hand eczema (long-lasting eczema affecting your hands)
- Your doctor believes delgocitinib cream is appropriate for you to try
- You have not previously used delgocitinib cream
- You are not currently enrolled in another clinical trial, or have not been in one in the past 12 months
- You are willing to provide written consent and let researchers review your medical records
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information about how well medications work for chronic hand eczema and how safe they are over time. You'll share your health data and treatment experiences through simple online forms to help doctors better understand which treatments work best.
This trial studies chronic hand eczema (and sometimes related atopic skin disease) to better understand your condition and what may be going on in the skin. You may be asked to follow a study plan for a set period and avoid certain treatments just before joining.
This trial tests a cream applied to the skin that may help control early-stage mycosis fungoides, a type of skin lymphoma. It aims to see if the cream can reduce symptoms and slow disease progression without the need for stronger treatments.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
This study looks at how certain proteins in the body (JAK and sodium channels) affect pain and itch. It tests a cream and a medication on healthy volunteers to see how they change the feeling of pain and itch.
Hear when a new Chronic Hand Eczema (CHE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.